ClinicalTrials.gg
CompletedNCT00656370INFUSE-NSLRUpdated Oct 17, 2018Results posted

Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)

A Phase 4 interventional study of recombinant human hyaluronidase in Healthy, sponsored by Halozyme Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-17.

Sponsored by Halozyme Therapeutics · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Randomized, double-blinded study that will evaluate the tolerability, safety, and flow rates of different solutions subcutaneously (SC) infused and preceded by human recombinant hyaluronidase (hylenex) 150 units.

In Stage 1, the comparison will be Normal Saline (NS) solution to Lactated Ringer's (LR) solution. Each subject will receive 500 milliliters (mL) of solution, consisting of NS in one thigh and LR in the other thigh. Immediately prior to the infusions, each thigh will have 150 units of hylenex.

In Stage 2, the comparison will be NS solution and buffered NS solution.

Read the detailed description

This Phase IV, randomized, double-blinded study in volunteer subjects to evaluate the tolerability, safety, and flow rates of different solutions subcutaneously (SC) infused and preceded by human recombinant hyaluronidase (hylenex) 150 units. The study will be conducted in two sequential stages.

In Stage 1, the comparison will be NS solution to LR solution. Each subject will receive simultaneous SC infusions of 500 mL (from a 500 mL bag) of solution in each anterior thigh, consisting of NS in one thigh and LR in the other thigh. The thighs (left vs. right) to receive NS and LR will be randomized and double blinded. Immediately prior to the infusions, each thigh will have 150 units of hylenex simultaneously injected.

Tolerability will be assessed based on the subject's self-assessment of discomfort on a visual analog scale (VAS). Safety will be assessed by physical examination targeted at infusion sites, vital signs, and adverse events. The amount of fluid infused will be assessed by weighing the infusion bag, fluid and tubing at designated time points, and allowing the determination of flow rate.

Stage 2 will be conducted only if the observed Stage 1 VAS mean maximum pain score is at least 25 mm higher for one solution compared to the other. Stage 2 will evaluate the tolerability, safety, and flow rates of subcutaneously infused NS solution and buffered NS solution.

02

Conditions studied

  • Healthy

Keywords

  • Hylenex
  • subcutaneous infusion
  • hyaluronidase
  • rHuPH20
  • recombinant human hyaluronidase
03

In context

Lead sponsor

Halozyme Therapeutics is the lead sponsor of 33 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, 18 to 60 years of age.
  2. Intact normal skin without in the areas intended for infusion.
  3. No fluid intake for 12 hours prior to the start of the study infusion.
  4. Vital signs (Blood Pressure (BP), Heart Rate (HR), Respiratory Rate (RR)) within normal range.
  5. Metabolic panel within normal range.
  6. A negative urine or serum pregnancy test.
  7. Signed, written Institutional Review Board (IRB)-approved .

Exclusion criteria

Exclusion Criteria:

  1. Lower extremity edema.
  2. Lower extremity pathology that could interfere with study outcome.
  3. Rales on lung auscultation.
  4. History of cardiovascular disease.
  5. Allergy to hyaluronidase.
  6. Allergy to bee or vespid venom.
  7. Pregnancy or breast-feeding woman.
  8. Use of any drug or device within 30 days of enrollment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    NS Infusion Group

    Normal Saline (NS) and Hylenex

    Drug: recombinant human hyaluronidase

  • Experimental
    LR Infusion Group

    Lactated Ringer's (LR) and Hylenex

    Drug: recombinant human hyaluronidase

Interventions

06

What researchers measure

Primary outcomes

  1. The Participant's Assessment of Discomfort at the Infusion Site on a Visual Analog Scale (VAS)

    Participant's self-assessment of discomfort at the infusion site by means of a validated VAS with a range of 0 millimeters (mm) (no discomfort) to 100 mm (worst possible discomfort), for the comparison of subcutaneous (SC) infusion of normal saline (NS) versus Lactated Ringer's (LR), each following an SC slow-push injection of 150 Units (U) Hylenex.

    Time frame: Approximate times which ranged from zero minutes at baseline to maximal post-infusion of 240 minutes on Day 1

Secondary outcomes

  1. Number of Participants Assessed for Safety Measures

    Safety outcome measures included adverse events (AEs), physical examinations (targeted physical examination included lung auscultation for rales, checking for edema, evaluation of infusion sites, positives on a review of systems, and follow-up of findings from previous physical examinations), and vital signs (systolic blood pressure, diastolic blood pressure, heart rate, and respiration rate).

    Time frame: Baseline, Mid-Infusion Right and Left, Post-Infusion Right and Left, Discharge Right and Left (up to approximately 8 days)

  2. Average Infusion Flow Rate (Milliliters Per Hour [mL/hr]) Derived From the Time to Infuse up to 500 mL of Solution

    The infusion flow rate (mL/h) was derived from the time to subcutaneously (SC) infuse up to 500 mL of NS or LR solution (following SC injection of 150 Units hylenex) by measuring the change in weight of the infusion bag, fluid, and tubing.

    Time frame: During infusion on Day 1

  3. Percent Change From Baseline Thigh Circumference to Maximum Post-Baseline Thigh Circumference at Infusion Sites

    Thigh circumference was measured in centimeters at 7 time points before, during, and after subcutaneous infusion of 500 mL NS or LR solution.

    Time frame: Before the infusion, during the infusion, after the infusion, and discharge (Day 1)

  4. Time From the Beginning of Infusion Until the Thigh Circumference Returns to Within 5% of Baseline Circumference

    Thigh circumference was measured at the level of the angiocatheter with a flexible measuring tape prior to infusion initiation (Baseline), at the midpoint for each infusion, and at the end of each infusion.

    Time frame: Before the infusion (Baseline) until discharge (Day 1)

  5. Number of Participant's With the Indicated Global Preference for Infusion (Left Versus Right Thigh)

    Participants blinded to the type of infusion were asked to state their preference for the left or right infusion following all infusion day (Day 1) activities and assessments. The preference for the left or right infusion indicated which infusion was preferred: NS or LR.

    Time frame: End of infusion (Day 1)

07

Results

Posted May 14, 2010

Participant flow

The first subject entered screening on 19 DEC 2007 and the last subject entered screening on 23 JAN 2008. A total of 25 subjects were assessed for eligibility and signed an Informed Consent Form.

Participant flow — Overall Study
MilestoneNS, LR
Started25
Completed15
Not completed10
Withdrew: Screen failures7
Withdrew: Alternates3

Outcome measures

PrimaryThe Participant's Assessment of Discomfort at the Infusion Site on a Visual Analog Scale (VAS)

Participant's self-assessment of discomfort at the infusion site by means of a validated VAS with a range of 0 millimeters (mm) (no discomfort) to 100 mm (worst possible discomfort), for the comparison of subcutaneous (SC) infusion of normal saline (NS) versus Lactated Ringer's (LR), each following an SC slow-push injection of 150 Units (U) Hylenex.

Time frame:
Approximate times which ranged from zero minutes at baseline to maximal post-infusion of 240 minutes on Day 1
Reported as:
Mean · mm
The Participant's Assessment of Discomfort at the Infusion Site on a Visual Analog Scale (VAS)
mmNS Infusion GroupLR Infusion Group
The Participant's Assessment of Discomfort at the Infusion Site on a Visual Analog Scale (VAS)20.0 ± 19.49.4 ± 18.3
SecondaryNumber of Participants Assessed for Safety Measures

Safety outcome measures included adverse events (AEs), physical examinations (targeted physical examination included lung auscultation for rales, checking for edema, evaluation of infusion sites, positives on a review of systems, and follow-up of findings from previous physical examinations), and vital signs (systolic blood pressure, diastolic blood pressure, heart rate, and respiration rate).

Time frame:
Baseline, Mid-Infusion Right and Left, Post-Infusion Right and Left, Discharge Right and Left (up to approximately 8 days)
Reported as:
Number · participants
Number of Participants Assessed for Safety Measures
participantsNS, LR
Number of Participants Assessed for Safety Measures15
SecondaryAverage Infusion Flow Rate (Milliliters Per Hour [mL/hr]) Derived From the Time to Infuse up to 500 mL of Solution

The infusion flow rate (mL/h) was derived from the time to subcutaneously (SC) infuse up to 500 mL of NS or LR solution (following SC injection of 150 Units hylenex) by measuring the change in weight of the infusion bag, fluid, and tubing.

Time frame:
During infusion on Day 1
Reported as:
Mean · mL/hr
Average Infusion Flow Rate (Milliliters Per Hour [mL/hr]) Derived From the Time to Infuse up to 500 mL of Solution
mL/hrNS Infusion GroupLR Infusion Group
Average Infusion Flow Rate (Milliliters Per Hour [mL/hr]) Derived From the Time to Infuse up to 500 mL of Solution384.1 ± 118.1395.8 ± 132.8
Statistical analysis
  • NS Infusion Group vs LR Infusion Group · Wilcoxon signed rank test · p = 0.93
SecondaryPercent Change From Baseline Thigh Circumference to Maximum Post-Baseline Thigh Circumference at Infusion Sites

Thigh circumference was measured in centimeters at 7 time points before, during, and after subcutaneous infusion of 500 mL NS or LR solution.

Time frame:
Before the infusion, during the infusion, after the infusion, and discharge (Day 1)
Reported as:
Mean · percent change
Percent Change From Baseline Thigh Circumference to Maximum Post-Baseline Thigh Circumference at Infusion Sites
percent changeNS Infusion GroupLR Infusion Group
Percent Change From Baseline Thigh Circumference to Maximum Post-Baseline Thigh Circumference at Infusion Sites5.2 ± 1.65.3 ± 1.5
Statistical analysis
  • NS Infusion Group vs LR Infusion Group · Wilcoxon signed rank test · p = 0.67
SecondaryTime From the Beginning of Infusion Until the Thigh Circumference Returns to Within 5% of Baseline Circumference

Thigh circumference was measured at the level of the angiocatheter with a flexible measuring tape prior to infusion initiation (Baseline), at the midpoint for each infusion, and at the end of each infusion.

Time frame:
Before the infusion (Baseline) until discharge (Day 1)
Reported as:
Mean · minutes
Time From the Beginning of Infusion Until the Thigh Circumference Returns to Within 5% of Baseline Circumference
minutesNS Infusion GroupLR Infusion Group
Time From the Beginning of Infusion Until the Thigh Circumference Returns to Within 5% of Baseline Circumference147.3 ± 35.6123.5 ± 9.7
SecondaryNumber of Participant's With the Indicated Global Preference for Infusion (Left Versus Right Thigh)

Participants blinded to the type of infusion were asked to state their preference for the left or right infusion following all infusion day (Day 1) activities and assessments. The preference for the left or right infusion indicated which infusion was preferred: NS or LR.

Time frame:
End of infusion (Day 1)
Reported as:
Count of participants · Participants
Number of Participant's With the Indicated Global Preference for Infusion (Left Versus Right Thigh)
ParticipantsNS Infusion GroupLR Infusion Group
Number of Participant's With the Indicated Global Preference for Infusion (Left Versus Right Thigh)015

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NS, LR—0/15 (0%)15/15 (100%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventNS, LR
Injection site painGeneral disorders11/15
Injection site erythemaGeneral disorders7/15
Injection site irritationGeneral disorders4/15
Injection site pruritusGeneral disorders2/15
HeadacheNervous system disorders2/15
Injection site bruisingGeneral disorders1/15
Oedema peripheralGeneral disorders1/15
PainGeneral disorders1/15
BronchitisInfections and infestations1/15
NasopharyngitisInfections and infestations1/15

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)NS, LR
<=18 years0
Between 18 and 65 years15
>=65 years0
Age, Continuous
Age, Continuous(years)NS, LR
Mean41 ± 14.9
Sex: Female, Male
Sex: Female, Male(Participants)NS, LR
Female14
Male1
Region of Enrollment
Region of Enrollment(participants)NS, LR
United States15
08

Study locations

1 site
  • Jasper Clinic
    Kalamazoo, Michigan 49007, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2010, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2008
First posted
Apr 11, 2008
Start
Dec 2007
Primary completionActual
Jan 30, 2008
CompletionActual
Jan 30, 2008
Results first posted
May 14, 2010
Last update
Oct 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00656370
Responsible party
Sponsor
First posted
Apr 11, 2008
Start date
Dec 2007
Primary completion
Jan 30, 2008
Completion
Jan 30, 2008
Results posted
May 14, 2010
Last update
Oct 17, 2018

Study contacts

Shanthini Daniel, M.D.
principal investigator · Jasper Clinic, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronidase (human recombinant)

Start the discussion